Although research is being conducted on Long COVID or Long COVID-19, whose symptoms continue for weeks and months after initial infection, there are very few ongoing clinical trials on treatments. Anecdotally, there has been what appears to be a successful treatment for Long Covid using Pfizer’s antiviral regimen Paxlovid.
On the strength of data from Alzamend Neuro’s Phase I study of its lead compound AL001 being developed for the treatment of Alzheimer’s disease, the company is looking to commence a Phase II multiple ascending dose study for that indication during the second quarter of 2022.
A new film produced by health creative agency The Bloc exposes the legacy of racial trauma. “Skindeep” is phase II of The Bloc’s series on racial trauma in America, taking a deeper look at the PTSD caused by the country’s divide.
Six months after a Covid-19 diagnosis, more than 33 percent of people exhibited some form of brain damage, according to a study appearing in Lancet Psychiatry.
Many Covid-19 survivors are likely to be at greater risk of developing mental illness, psychiatrists said, after a large study found 20% of those infected with the coronavirus are diagnosed with a psychiatric disorder within 90 days.
Aptinyx Jumps Following Positive Phase II PTSD Study Results Published: Oct. 20, 2020 By Alex Keown BioSpace Shares of Aptinyx skyrocketed more than 75% after the company reported its […]
